Clinical Trial Update: An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating nivolumab versus placebo in patients with resected esophageal or gastroesophageal junction cancer has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• OPDIVO (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Advanced Cancer | Phase 3 | Status: COMPLETED | Results posted: 2021-06-22